Abstract 309P
Background
The American College of radiology proposed BI-RADS lexicon lacks defined rules which direct conversion of specific imaging features into a diagnostic category, results in a discrepancy of reporting. This study compares results from multilayer Perceptron neural network and a classification tree.
Methods
A total of 316 lesions with successive histological verification (221 malignant, 95 benign) were investigated. Six lesion criteria's were assessed by 2 readers in consensus. Classification analysis was performed using the chi-squared automatic interaction detection (CHAID) method. Results include the probability for malignancy for every descriptor combination in the classification tree. Simultaneously a multilayer Perceptron neural network was developed by using SPSS software.
Results
A classification tree incorporating 6 lesion descriptors with a depth of 4 ramifications (1- ADC values; 2 -root sign; 3- enhancement pattern; 4 - oedema) was calculated. Of all 316 lesions, 38 (40 %) and 212 (95.9 %) could be classified as benign and malignant with an accuracy above 95 %, respectively. Overall diagnostic accuracy was 79.1 %. The multilayer perceptron network segregated the lesions into training and testing sets in a ratio of 7:3. With a hyperbolic tangent activation function, there were six units of hidden layer and the model show a 20% and 17% incorrect predictions in the training in the testing sets. The diagnostic accuracy of malignant and benign lesions was 92% and 52 % in both the training and testing sets. The area under the curve of the ROC was .855. The order of importance of synaptic weights calculated from the model were ADC ( 0.257), Internal enhancement (0.233), ROOT SIGN (0.175), Margins (0.138), Curve type (0.138), edema (0.038) and mass / non mass (0.021).
Conclusions
The classification algorithm correctly classified 95 % malignant lesions with accuracy above 95 %. The neural network model showed good results on internal validation and revealed ADC to be the most significant parameter with the least importance to morphological classification into mass and non-mass lesions. Also, the dynamic contrast curve patterns were more significant than margins.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Rajiv Gandhi Cancer Institute and Research Center.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
403P - Clinical profile, practice pattern and outcomes in ALK-positive lung cancer: Real-world data from India
Presenter: Akhil Kapoor
Session: e-Poster Display Session
404P - Financial toxicity in patients with advanced lung cancer treated with immunotherapy: Has it an effect on the clinical decision?
Presenter: Jia-Hui Weng
Session: e-Poster Display Session
405P - Promising efficacy as combination therapy of DFP-14323, protease inhibitor, with EGFR-TKI in patients with metastatic NSCLC harboring EGFR mutation
Presenter: Hiroshige Yoshioka
Session: e-Poster Display Session
406P - Anti-PD-1 versus anti-PD-L1 inhibitors in first-line therapy non-small-cell lung cancer: A systematic review and meta-analysis
Presenter: Angelo Brito
Session: e-Poster Display Session
407P - Integrating histologic and genomic characteristics to predict tumour mutation burden of early-stage non-small cell lung cancer
Presenter: Yuan Qiu
Session: e-Poster Display Session
408P - Integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutation
Presenter: Julia Maevskaya
Session: e-Poster Display Session
409P - Effect of transdermal granisetron on prevention of nausea and vomiting during chemotherapy of lung cancer
Presenter: Haifeng Qin
Session: e-Poster Display Session
410P - Frequency and spectrum of primary resistance mechanism in Chinese ALK+ non-small cell lung cancer patients progressing on crizotinib: A multicenter study
Presenter: Wen-xian Wang
Session: e-Poster Display Session
411P - Impact of pre-treatment AXL expression on osimertinib efficacy in patients with non-small cell lung cancer with EGFR mutation
Presenter: Yoshihiko Taniguchi
Session: e-Poster Display Session
412P - Treatment patterns and selection criteria for advanced non-small cell lung cancer (NSCLC) patients unfit for platinum-based first-line therapy: Results of the MOON-OSS observational trial
Presenter: Andrea Camerini
Session: e-Poster Display Session